COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies by Philip C Robinson, Thomas S Uldrick, Jason D Goldman, Per Ljungman

Get full text

Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXIDResear... by Puran Chen, Peter Bergman, Ola Blennow, Lotta Hansson, Stephan Mielke, Piotr Nowak, Yu Gao, Gunnar Söderdahl, Anders Österborg, C.I.Edvard Smith, Jan Vesterbacka, David Wullimann, Angelica Cuapio, Mira Akber, Gordana Bogdanovic, Sandra Muschiol, Mikael Åberg, Karin Loré, Margaret Sällberg Chen, Per Ljungman, Marcus Buggert, Soo Aleman, Hans-Gustaf Ljunggren

Get full text

A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol by Vanessa Smith, Ellen De Langhe, Jacob M van Laar, Alexandre E Voskuyl, Madelon C Vonk, Roger Hesselstrand, Ulrich A Walker, Dirk M Wuttge, Reinhard E Voll, Arjan A van de Loosdrecht, Julia Spierings, Joerg Henes, Anna van Rhenen, Paco MW Welsing, Anne CA Marijnissen, Nicoletta Del Papa, Daan Dierickx, Karina R Gheorghe, Tessa Kerre, Per Ljungman, Erik WAF Marijt, Miro Mayer, Marc Schmalzing, Roland Schroers, Jeska K de Vries-Bouwstra

Get full text